Avelumab - novinka v léčbě pacientů s metastazujícím karcinomem z Merkelových buněk
| Title in English | Avelumab - a novelty in the treatment of patients with metastatic carcinoma of Merkel cells |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Onkologická revue |
| Citation | |
| Keywords | Merkell cell carcinoma;immunotherapy;avelumab |
| Description | Merkell cell carcinoma (MCC) is a rare aggresive skin neuroendocrine cancer, metastatic disease is associated with poor prognosis and overal survival. The efficacy of avelumab in the JAVELIN Merkell 200 registration study in metastatic MCC refraktory to chemotherapy patients and also in untreated chemotherapy naive patients with MCC resulted in its approval by the Food adn Drug Administration (FDA) in the US in March 2017 and subsequently in Europe in September 2017. The administration of avelumab in advanced MCCs on both first and subsequent treatment lines has shown prolongation of the interval in both progression and overall survival and good safety profile with manageable side effects. |